ARA-290 modulates EPO receptors, activating protective mechanisms in nervous and vascular tissue. Reduces neuroinflammation, reduces pain, improves microcirculation and vascular barrier function. It is used for diabetic complications and autoimmune diseases.
Raw MaterialUSA
Country of OriginUAE
Purity99%
Raw MaterialUSA
Purity99%
Country of OriginUAE
Indications
Diabetic neuropathy
Systemic inflammatory diseases
Vascular and neurovascular complications
Support for autoimmune conditions
Post-viral neuropathy
Contraindications
Central Nervous System Tumors
Acute Infections
Pregnancy, Lactation
Idiosyncrasy.
ARA-290 is a selective non-erythropoietic peptide that activates tissue-protective pathways, normalizes inflammatory signaling, and enhances reparative processes. By regulating cytokine expression, the peptide reduces cellular inj...
ARA-290 is a selective non-erythropoietic peptide that activates tissue-protective pathways, normalizes inflammatory signaling, and enhances reparative processes. By regulating cytokine expression, the peptide reduces cellular injury under metabolic stress, improves microcirculation, and strengthens the functional resilience of nerve fibers.
ARA-290 is incorporated into protocols focused on neuronal support, correction of neuropathic symptoms, endothelial recovery, and enhancement of cellular resistance to inflammation and stress. Regular use is associated with improved sensory function, reduced discomfort, and increased nerve-conduction efficiency.
ARA-290 is suitable for patients who need nervous-system restoration, reduced neuroinflammation, improved tissue sensitivity, and enhanced microvascular function. It is utilized in post-neuropathy recovery schemes, anti-inflammatory protocols, and strategies aimed at reinforcing endothelial protection and optimizing neurovascular health.